Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- Paul Szabolcs
- Study ID
- NCT04528355
- Status
- Recruiting
Conditions
- Congenital Bone Marrow Failure Syndromes
- Hereditary Anemias
- Inflammatory Conditions
- Inherited Metabolic Disorders (IMD)
- Primary Immunodeficiency (PID)
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Months - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- data collection — DRUGStudy subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
Study Details
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
Key Dates
- Start date
- Aug 20, 2020
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2027
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 50 participants (estimated)
Primary Outcome Measure
incidence of acute graft versus host disease (GVHD) [ Time Frame: up to 5 years ]
Central Contacts
- Paul Szabolcs, MD412-692-5427
- Shawna McIntyre, RN412-692-5552
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UPMC Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15224 | Jessie Barnum, MD (SUB_INVESTIGATOR) Craig Byersdorfer, MD (SUB_INVESTIGATOR) Maria Escolar, MD (SUB_INVESTIGATOR) Elizabeth Stenger, MD (SUB_INVESTIGATOR) Randy Windreich, MD (SUB_INVESTIGATOR) |
Find similar trials in Pittsburgh, PA
By research site
Related Studies
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTPHASE2 · Recruiting · Paul Szabolcs · Pittsburgh, Pennsylvania
- Clinical Genetics Branch Eligibility Screening SurveyNot Yet Recruiting · National Cancer Institute (NCI) · Rockville, Maryland
- Prenatal Transplantation for Fetuses With Fanconi AnemiaPHASE1/PHASE2 · Not Yet Recruiting · Agnieszka Czechowicz · San Francisco, California